New hope for cancer patients after UK drugs trial - Stoke-on-Trent Live
stokesentinel.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from stokesentinel.co.uk Daily Mail and Mail on Sunday newspapers.
iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ALLO) - The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Chief Executive Officer
Karen E. Knudsen, MBA, Ph.D., is the chief executive officer of the American Cancer Society (ACS) and its advocacy affiliate, the American Cancer Society Cancer Action Network
SM (ACS CAN). As a well-respected cancer leader, researcher, and advocate, Dr. Knudsen guides the organization on our mission to save lives, celebrate lives, and lead the fight for a world without cancer. She has a strong commitment to ensuring that all people can benefit from the impact of our work.
Prior to joining ACS, Dr. Knudsen served as executive vice president of Oncology Services and enterprise director for Sidney Kimmel Cancer Center at Jefferson Health, one of only 71 National Cancer Institute-designated cancer centers recognized for their research and impact on cancer outcomes. While at Sidney Kimmel Cancer Center at Jefferson Health, Dr. Knudsen experienced firsthand how ACS improves the lives of cancer patients and their families through discovery, advocacy, and patient
May 24, 2021 8:00am The phase 1 trials focused on gauging the safety and tolerability of the bispecifics, but the efficacy results look “extremely promising” to a very sick patient group, the majority of whom had no luck with their last line of therapy, Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit. (Hailshadow/GettyImages)
Johnson & Johnson finished the FDA filing for its anti-BCMA CAR-T in multiple myeloma last month, but that doesn’t mean it’s letting off the gas. The drugmaker revealed phase 1 data for two bispecific antibodies showing they shrank the tumors of about 70% of patients whose cancer got worse despite trying several other treatments, including the three main types of myeloma-fighting drugs.